S-1/A: United Health Products Files for Resale of 15 Million Shares of Common Stock

United Health Products registers 15 million shares for resale by White Lion Capital under existing purchase agreement.

Summary

• United Health Products, Inc. has filed a registration statement for the resale of up to 15,000,000 shares of its common stock.
• These shares may be issued to White Lion Capital, LLC under a Common Stock Purchase Agreement (CSPA).
• The company previously registered 15,000,000 shares for resale on Form S-3 (Registration No. 333-267310), which included commitment shares and purchase notice shares.
• As of the prospectus date, UHP has sold 14,240,000 shares to White Lion for approximately $3,000,000, leaving $7,000,000 worth of shares available for future sales.
• This new registration statement on Form S-1 covers an additional 15,000,000 shares for resale under the CSPA.
• White Lion may sell these shares from time to time on otcmarkets.com or other trading facilities, or in private transactions.
• UHP will not receive any proceeds from the resale of shares by White Lion, but may receive proceeds from the sale of shares to White Lion under the CSPA.
• The last reported sale price of UEEC common stock on July 12, 2024, was $0.1875 per share.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on the mechanics of a stock resale registration. The risks outlined are balanced by the potential for future revenue growth, but the lack of current profitability and dependence on future financing temper any strong positive outlook.

Risks

• The market price of the stock has been and may continue to be highly volatile.
• The low trading volume of the common stock may adversely affect the price of the shares and their liquidity.
• The company may in the future seek to raise funds through equity offerings, which could have a dilutive effect on the common stock.
• Sales of a significant number of shares of the common stock in the public markets, or the perception that such sales could occur, could depress the market price of the common stock.
• There is currently no established market for the common stock, and the company cannot ensure that one will ever develop or be sustained.
• The common stock is deemed a penny stock, which may make it more difficult for investors to sell their shares.
• The company has a history of operating losses and may continue to lose money in the future.
• The company can provide no assurances that its Class III application for internal surgical procedures in the U.S. market will be approved by the FDA.
• The company will need additional financing to execute its business plan and fund operations, which may not be available.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.

Future Outlook

The company is evaluating paths to rapidly grow revenue and profits in all potential market segments, with the objective of maximizing shareholder value, including a potential sale or merger of the company or commercial partnerships.

Industry Context

The document relates to the capital markets activity of a small company in the healthcare sector, specifically regarding the resale of its common stock. This is a common practice for companies seeking to raise capital, but it also highlights the risks associated with investing in smaller, less liquid stocks.

Stakeholder Impact

• Shareholders may experience dilution if additional shares are issued to White Lion.
• The company's ability to execute its business plan depends on securing additional financing.
• The company's future success depends on obtaining regulatory approvals and penetrating target markets.

Next Steps

• White Lion Capital may sell the registered shares from time to time.
• The company may issue additional shares to White Lion under the CSPA.
• The company is awaiting a decision from the FDA on its Class III PMA application.
• The company is evaluating potential commercial partnerships and a possible sale or merger.

Key Dates

Keywords

common stock, resale, White Lion Capital, CSPA, registration statement, shares, UEEC, United Health Products